Skip to content
Clinical Trials – home

Find therapies in clinical trials near you – page 60

recruiting
3 987
countries
28
conditions
2 109

1 026 trials match your criteria

Type 2 diabetes mellitus+2

Not recruiting

Study of NNC0519-0130 and semaglutide in people with chronic kidney disease who are overweight or obese, with or without type 2 diabetes

Registered drug
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Semaglutide

Colitis ulcerative

Not recruiting

Study on the Effects of Zasocitinib for Patients with Moderate to Severe Ulcerative Colitis

Investigational
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Zasocitinib

Study on Ustekinumab and Guselkumab for Children with Active Juvenile Psoriatic Arthritis

Registered drugNo placebo
Countries:PolandPoland
  • Participants:0–17 years
  • Substances:Guselkumab

Study on Tolebrutinib for Patients with Primary Progressive Multiple Sclerosis

Investigational
Countries:PolandPoland
  • Participants:18–64 years
  • Substances:Tolebrutinib

Study on Palbociclib and Endocrine Therapy for Patients with HR+/HER2- Early Breast Cancer

InvestigationalNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Palbociclib

Study on Acalabrutinib, Venetoclax, and Obinutuzumab for Untreated Chronic Lymphocytic Leukemia Patients Without del(17p) or TP53 Mutation

Registered drugNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Acalabrutinib

Study on Fenebrutinib and Teriflunomide for Adults with Relapsing Multiple Sclerosis

Registered drug
Countries:PolandPoland
  • Participants:18–64 years
  • Substances:Fenebrutinib

Crohn's disease

Not recruiting

Study on Guselkumab for Patients with Moderate to Severe Crohn's Disease

Investigational
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Guselkumab

Parkinson's disease

Not recruiting

Study on the Effects and Safety of Prasinezumab for Patients with Early Parkinson's Disease

Investigational
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Prasinezumab

Study on Long-Term Safety and Effectiveness of Ofatumumab for Patients with Relapsing Multiple Sclerosis

Registered drugNo placebo
Countries:PolandPoland
  • Participants:18–64 years
  • Substances:Ofatumumab

Dermatitis atopic

Not recruiting

Study on the Effectiveness of Ruxolitinib Cream for Adults with Moderate Atopic Dermatitis

Investigational
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Ruxolitinib
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.